Trial Profile
A Phase 1a/1b Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Mar 2022
Price :
$35
*
At a glance
- Drugs Cabiralizumab (Primary) ; Nivolumab (Primary)
- Indications Glioma; Head and neck cancer; Lung cancer; Malignant melanoma; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Five Prime Therapeutics
- 29 Jul 2020 Status changed from active, no longer recruiting to completed.
- 30 Aug 2019 Planned primary completion date changed from 1 Mar 2019 to 1 Feb 2020.
- 27 Sep 2018 Planned End Date changed from 1 Aug 2019 to 1 Mar 2020.